[1] ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing, Retrieved March 08, 2020, from https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/